ArticleDiscover nano2025
Oral delivery of dextran-modified albumin nanoparticles loaded with shikonin for targeted therapy of colorectal cancer.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Pyruvate Kinase M2: Signal Transduction Pathways and Exploration of Cancer Therapeutic Strategies.The AAPS journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide.
methodsIn this study, we developed a novel nanomedicine-based therapeutic approach targeting key molecules involved in the progression of CRC. By utilizing bioinformatics tools and computer simulations, we identified SLC2A1 and PKM2 as potential therapeutic targets for CRC. Through molecular docking, we confirmed that shikonin (SHK), a bioactive compound derived from traditional herbal medicine, could effectively bind to SLC2A1 and PKM2, indicating its potential therapeutic effect. The novel SHK-loaded nanoplatform, functionalized with albumin (BSA) and glycoside modification (gBSA/SHK), was designed to enhance stability and targeted delivery to tumor sites.
resultsIn vitro and in vivo experiments showed that SHK-loaded nanoparticles exhibited good tumoricidal effects on CT26 colorectal cancer cells and shifted tumor cell metabolism.
conclusionsOverall, our results suggest that SHK-loaded nanodrugs can effectively target key molecular pathways in CRC and provide a promising strategy for colorectal cancer treatment with advantages such as improved drug stability, tumor-specific targeting, and reduced systemic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.